Treatment options expanding for advanced melanoma.

Abstract

Immunotherapies and BRAF and MEK inhibitors have dramatically improved outcomes in advanced melanoma. The availability of these novel approaches has necessitated changes to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). The NCCN Guidelines feature algorithms that aid clinicians in selecting initial therapy, which now includes anti-programmed death protein receptor-1 PD-1 inhibitors among the recommended systemic therapy options for patients with metastatic or unresectable disease.

• Authors: John A Thompson
• Journal: Journal of the National Comprehensive Cancer Network : JNCCN (J Natl Compr Canc Netw) Vol. 13 Issue 5 Suppl Pg. 673-5 (May 2015) ISSN: 1540-1413 [Electronic] United States
• PMID: 25995427 (Publication Type: Journal Article)
• Copyright: Copyright © 2015 by the National Comprehensive Cancer Network.

Chemical References

• Antineoplastic Agents
• Protein Kinase Inhibitors
• Proto-Oncogene Proteins B-raf

Topics

• Antineoplastic Agents (therapeutic use)
• Humans
• Immunotherapy (methods)
• Medical Oncology (standards)
• Melanoma (drug therapy, immunology)
• Practice Guidelines as Topic
• Protein Kinase Inhibitors (therapeutic use)
• Proto-Oncogene Proteins B-raf (metabolism)